Prescription-Eyeglasses.com - Brand name eyeglasses, Frames, contact lenses, Sunglasses, Safety Glasses, and Quality Replacement Lenses at the most affordable prices

Shop Our Products

News

Once-daily netarsudil noninferior to twice-daily timolol in phase 3 study

Once-daily netarsudil was noninferior to twice-daily timolol for IOP-lowering efficacy in patients with open-angle glaucoma or ocular hypertension, according to the phase 3 ROCKET-4 study. In ROCKET-4, a large multicenter trial that was published in the American Journal of Ophthalmology this year, netarsudil once daily was noninferior to timolol used twice day. This effect persisted at various baseline IOPs for the duration of the study. There were no systemic side effects for netarsudil, unlike...

>Read More

Spectacle wear increases due to vision correction, decreases due to bullying

Adherence to spectacle wear is higher in students with poor presenting visual acuity and greater improvement in visual acuity with correction. Additionally, researchers found that teasing and bullying by peers was the most frequently reported reason for nonwear in children, according to a study published in JAMA Ophthalmology. Our findings support the use of prescribing guidelines, which in this study was that the corrected visual acuity (VA) had to improve by two or more lines in the better eye...

>Read More

Graybug Vision completes Series C financing

Graybug Vision has closed $80 million in Series C financing, which will be used to advance its pan-VEGF inhibitor GB-102 into phase 2 studies and its potential glaucoma treatment GB-401 into the clinic, according to a press release. The financing was led by CBC Group and includes participation from Deerfield Management, OrbiMed Advisors and Hatteras Venture Partners. A phase 2b clinical study of GB-102, a potential twice-a-year treatment, is planned for the treatment of wet age-related macular d...

>Read More

One health system's experience relevant to looming price transparency rule

The Trump administrations ongoing effort to lower health care costs and increase transparency resumes later this summer when HHS is expected to propose a rule that explains how hospitals would be required to disclose the amount patients would pay for services before they receive care. Data indicate the toll medical costs are taking on Americans. A PLoS One study found that 9% of American households had medical debt in 2013, with the bill totaling nearly $3,000 in some instances. A report in The ...

>Read More

Omeros posts lower net loss in second quarter

Omeros reported a second quarter net loss of $14.5 million, or $0.29 per share, compared with a net loss of $33.7 million, or $0.70 per share, in the second quarter of 2018, according to a press release. Revenue increased from $26.8 million in the second quarter compared with $1.7 million in the second quarter of 2018 and $21.8 million in the first quarter of 2019. All second quarter revenue was attributed to sales of Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution), which is b...

>Read More

Alcon launches daily disposable contact lens in new material

Alcon announced the September launch of Precision1 daily disposable contact lenses, which the company said were designed to provide long-lasting comfort and ease of handling. The proprietary SmartSurface technology uses a micro-thin, high-performance layer of moisture at the lens surface to help support a stable tear film and allow for precise vision and dependable comfort throughout the day, Sean Clark, general manager of Alcon U.S. vision care, said in a company webcast. Clark explained how th...

>Read More

Aerie begins trial of sustained release drug for retinal disease

Aerie Pharmaceuticals has initiated a clinical trial of AR-13503, a sustained release implant, for treatment of neovascular age-related macular degeneration or diabetic macular edema, according to a press release. The implant, which is made of bio-erodible polyesteramide polymer, is designed for once every 6-month dosing by intravitreal injection. The small molecule drug inhibits both Rho kinase and protein kinase C over a sustained period. The first-in-human clinical trial will include two phas...

>Read More